These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33788389)

  • 41. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.
    Elitzur S; Arad-Cohen N; Barzilai-Birenboim S; Ben-Harush M; Bielorai B; Elhasid R; Feuerstein T; Gilad G; Gural A; Kharit M; Litichever N; Nirel R; Weinreb S; Wolach O; Toren A; Izraeli S; Jacoby E
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27898. PubMed ID: 31264788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blinatumomab-induced macrophage activating syndrome (MAS) in adult with B-cell acute lymphoblastic leukemia (B-ALL).
    Braun A; Otoukesh S; Tinajero J; Marcucci G; Aldoss I
    Ann Hematol; 2024 Jul; 103(7):2541-2543. PubMed ID: 38789590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blinatumomab for the treatment of B-cell lymphoma.
    Oak E; Bartlett NL
    Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Super-refractory status epilepticus during blinatumomab initiation for B-cell acute lymphoblastic leukemia.
    Rao CK; Kamoroff S; Zorrilla J; Joyce M; Galan FN
    Immunotherapy; 2022 Dec; 14(18):1437-1442. PubMed ID: 36617960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia.
    Fuster JL; Bautista F; González B; Fernández JM; Rives S; Dapena JL;
    Clin Transl Oncol; 2021 Sep; 23(9):1963-1966. PubMed ID: 33742341
    [No Abstract]   [Full Text] [Related]  

  • 50. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.
    Lu J; Bao X; Zhou J; Li X; He Z; Ji Y; Xue S; Chen S; Wu D; Hu Q; Ke P; Ma X
    Blood Cancer J; 2024 Aug; 14(1):143. PubMed ID: 39179531
    [No Abstract]   [Full Text] [Related]  

  • 52. Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review.
    Sora F; Annunziata M; Laurenti L; Giammarco S; Chiusolo P; Innocenti I; Autore F; Metafuni E; Galli E; Bacigalupo A; Ferrara F; Sica S
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29044. PubMed ID: 33844429
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
    Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.
    Stein AS; Larson RA; Schuh AC; Stevenson W; Lech-Maranda E; Tran Q; Zimmerman Z; Kormany W; Topp MS
    Blood Adv; 2018 Jul; 2(13):1522-1531. PubMed ID: 29954814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.
    Mejstríková E; Hrusak O; Borowitz MJ; Whitlock JA; Brethon B; Trippett TM; Zugmaier G; Gore L; von Stackelberg A; Locatelli F
    Blood Cancer J; 2017 Dec; 7(12):659. PubMed ID: 29259173
    [No Abstract]   [Full Text] [Related]  

  • 57. Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data.
    Vakharia P; Nardone B; Budris W; Hoshizaki K; Frankfurt O; West DP
    Leuk Lymphoma; 2018 Jul; 59(7):1759-1761. PubMed ID: 29115884
    [No Abstract]   [Full Text] [Related]  

  • 58. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
    Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.